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Introduction
Immune checkpoint blockade therapies have been pro-
ven to elicit clinical responses in clear cell renal cell car-
cinoma (ccRCC) patients. A comprehensive profiling of
the tumor landscape is however still required and will
help to explain how for this cancer, the high densities of
infiltrating CD8+ T cells have previously been correlated
with a poor clinical outcome. Studies analyzing the
tumor immunome often examine gene expression from
the complete specimen, which is an overlap of expres-
sion profiles from the many different cell types from
this microenvironment, and which may make results dif-
ficult to interpret. Therefore, we aimed to profile and
validate the gene expression signatures from individual
CD4+ and CD8+ immune cell subsets isolated from
freshly resected ccRCC patient tumors and blood for
their comparison to those from normal kidney tissues
and blood, respectively.
Experimental methods
CD4+ and CD8+ T lymphocytes were isolated from blood
and freshly resected tissues, and RNA was subjected to
microarray analysis. Gene expression from a number of
resulting targets of interest (immune checkpoints, tran-
scription factors, cytokine/chemokines and receptors, sig-
naling molecules and cytotoxicity markers) were validated
using qPCR with the HD Biomark allowing coexpression
analysis. Multi-parametric flow cytometry and immuno-
fluorescence were then used to validate the coexpression
of immune checkpoint modulators – the coexpression of
which was also estimated using survival plots generated
from The Cancer Genome Atlas (TCGA) to provide prog-
nostic relevance to our findings.
Results, conclusions and perspectives
Our findings reveal a differential expression profile of
many genes, including immune checkpoint controllers,
between the CD4+ and CD8+ T cells isolated from
patient tumors and blood relative to normal kidney tis-
sues and normal donor blood. Our four different
sources of T cell isolation allows the discrimination of
the differential expression of genes as a function of the
disease rather than that of anatomical location. Our
work may explain why a high infiltrate of CD8+ T cells
in ccRCC has been associated to poor clinical outcome,
reveal the mechanisms by which this might occur, and
provide new strategies for immune checkpoint blockade
therapies.
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